A CHEST 2026 records analysis of roughly 2 million patients found 1.4% versus 2.3% at one year. The authors say it shows an association, not proof the drugs caused it.
Recap by typeshit. Full story at Medical Daily.
Researchers are studying whether GLP-1 drugs, which act on mood, appetite and reward pathways, could help with depression, addiction and binge eating.
A retrospective cohort checks whether retinal disease started or worsened more in established users than in people never on either drug, plus a regional NAION review.
24:34
An animated explainer walking through what semaglutide does in the body, from appetite signals in the brain to digestion and blood sugar control.
In rats and minipigs, doses too small to cut weight still reduced heart scarring and stiffness tied to a common heart failure type, researchers report.
11:54
Ryan Sims of Optimal Health Project gives a follow-up on how things have gone in the months since his 35-pound loss on the experimental drug.
The Tico Times reports Costa Rica's public system is considering offering GLP-1 weight loss drugs to patients. Tap through for where the discussion stands.
Loading…